in vivo gene editing

Metagenomi's compact CRISPR nuclease achieves 64% protein knockdown in mice via single AAV injection, validating its approach for non-hepatic genome editing therapies.

CRISPR Therapeutics reports strong Q4 results with Casgevy gene therapy generating $116M revenue and 147 patient initiations, signaling accelerating adoption and market confidence.